 We will test this hypothesis by performing a 13-week open label study investigating the use of memantine, at a dose of 10-40mg daily, as a treatment for patients with either bulimia nervosa or body dysmorphic disorder. Improvement for patients with bulimia nervosa will be assessed using the Frequency of binge eating and vomiting as recorded in diary card, Eating Disorder Evaluation EDE, and the Yale-Brown-Cornell Eating Disorders Scale YBC-EDS. Improvement for patients with body dysmorphic disorder will be assessed using the the Yale-Brown-Cornell Eating Disorders Scale YBC-EDS and Brown Assessments of Beliefs Scale. In addition both groups will also receive the Clinical Global Impression CGI Severity and Improvement Scales clinician rated, Patient Global Impression of Improvement PGI-Improvement, Montgomery Asberg Depression Rating Scale MADRS, Hamilton Anxiety Rating Scale HAM-A, Barratt Impulsiveness Scale BIS, Version 11, Sheehan Disability Scale SDS, and Columbia Suicide Severity Rating Scale C-SSRS. 